



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 29 Jan 2019 (#3)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important Notices

- **NIH-South Africa MRC (R01 and U01):** <https://grants.nih.gov/grants/guide/notice-files/NOT-AI-19-032.html>. The intent of this program is to foster, stimulate, and/or expand basic, translational, behavioral and applied research that will advance scientific discovery and engage U.S. and South African researchers working collaboratively in the areas of HIV/AIDS, HIV/AIDS-associated malignancies, and other infectious diseases. Estimated Application Due Date: 26 July 2019  
**TIP:** Potential applicants can contact RGMO to discuss timelines, requirements and start with updating biosketches using ScienCV <https://www.ncbi.nlm.nih.gov/sciencv/>
- **[Is your grant ending within the next year? Plan now to avoid a funding gap.](#)** Whether you are on your first grant or you have had decades of support, renewal is never guaranteed! Only about one-third of renewal applications have succeeded and most of those failed on the first attempt. You can take steps to keep a steady flow of funding.
- **[Learn how investigators conducting human subjects research can comply with the Final Rule on the Federal Policy for the Protection of Human Subjects \(Common Rule\), which went into effect 21 January 2019.](#)** You should be aware of several provisions: such as 1) institutional review boards (IRBs) no longer having to review and approve entire grant applications or contract proposals,\* 2) annual IRB reviews not being mandatory unless certain circumstances apply, 3) changes to categories of research that qualify for an exemption, and 4) investigators of clinical trials having to post informed consent documents on a public federal website after recruitment closes and no later than 60 days after the last study visit.
- **[Application guidance for using clinical trial data or samples from another study.](#)** NIH does not consider studies that involve secondary research with biological specimens or health information to be clinical trials. When applying to fund such a study, you should provide a short description of the source of the data or samples while being clear that the proposed research is not a clinical trial.

### 1. Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-CA-19-032\)](#)

**Type:** R01

**Application Due Date:** August 1, 2019; August 3, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen. This FOA is patterned on, but unrelated to, a series of FOAs for "Research Answers to NCI's Provocative Questions".

**Budget:** NCI intends to commit \$4,000,000 in FY 2021 to fund 6-8 awards. Application budgets are not limited but need to reflect the actual needs of the proposed R01 project. The total project period may not exceed 5 years.

### 2. Establishing a Cohort to Clarify Risk and Protective Factors for Neurocognitive Complications of Pediatric Type 1 Diabetes (T1D) - Planning Cooperative Agreements (U34 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-DK-18-007\)](#)

**Type:** U34

**Application Due Date:** April 11, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This FOA invites applications for planning cooperative agreements (U34) for a national, multisite, observational cohort study to prospectively examine the risk and protective factors for neurocognitive complications of pediatric type 1 diabetes (T1D; onset approximately ages 5-10 years) and a comparison sample. The U34 is designed to: 1) Permit early peer review of the rationale for the proposed cohort study; 2) Permit assessment of the study design; and 3) Provide support for the development of essential elements required for the design and conduct of the cohort study and the management and analysis of the study data. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

**Budget:** NIDDK intends to commit \$1.25 million in FY 2019 to fund up to 3 awards. Budgets for direct costs of up to \$225,000 per year are allowed. The funds requested are expected to vary based on the number of clinical centers involved in the study and the complexity of the study. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 3. Development and Validation of Advanced Mammalian Models for Alzheimers Disease-Related Dementias (ADRD) (R61/R33 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-19-167\)](#)

**Type:** R61/R33

**Application Due Date:** March 14, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) encourages research to develop, characterize and validate innovative mammalian models that recapitulate molecular, cellular, neuropathological, behavioral and cognitive hallmarks of the Alzheimer's Disease-Related Dementias (ADRD), including Lewy body dementia (LBD), vascular contributions to cognitive impairment and dementia (VCID), frontotemporal degeneration (FTD) and mixed etiology dementias (MED). Models will be expected to exhibit a broad range of features characteristic of the dementia disorder being modeled, including a mid- to late-life onset consistent with the human disorder, multiple age-dependent neuropathological processes and the associated behavioral, cognitive and/or physiological abnormalities. For each proposed mammalian model, a relevant suite of phenotypes that inform human ADRD disease progression and mechanisms should be characterized across the full life span or, for longer-living mammalian models, throughout the disease-relevant stages of adulthood. The goal of this FOA is to establish multi-dimensional mammalian models for ADRD to serve as tools to interrogate molecular disease mechanisms and identify therapeutic targets.

**Budget:** NIH intends to commit up to \$2,800,000 in FY 2019. NINDS intends to fund up to 4 awards, and NHLBI intends to fund up to 1 award. Application budgets are not limited but need to reflect the actual needs of the proposed project. The project period for the R61 phase is limited to a maximum of 3 years. The project period for the R33 phase is limited to a maximum of 3 years. The entire award project period may not exceed 5 years total. Conversion to the R33 phase is contingent on completion of milestones in the R61 award period.

### 4. Progression Markers for Cognitive Impairment in Parkinson's Disease Dementia (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-19-170\)](#)

**Type:** R01

**Application Due Date:** March 8, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The goal of this Funding Opportunity Announcement (FOA) is to encourage applications that propose to identify biomarkers for onset and progression of cognitive impairment in Parkinson's Disease (PD) through Parkinson's Disease Dementia (PDD). The use of well-characterized populations of PD and PDD patients that have been, and can continue to be, followed longitudinally with clinical assessments and biospecimen collection to autopsy should be considered.

**Budget:** NIH intends to fund an estimate of 5-7 awards, corresponding to a total of \$5,000,000, for fiscal year {2019}. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 5. Biology of Bladder Cancer (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-19-168\)](#)  
[\(PAR-19-169\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.

**Budget:** R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. R21 - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in a single year.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: *Christa* • Tel: 9838 • Email: [cde.vries@sun.ac.za](mailto:cde.vries@sun.ac.za)